Key Takeaways & Executive Findings
- •• • The combination of electroacupuncture and conventional rehabilitation improved GMFM scores by 13.5 points (from 45.2±8.3 to 58.7±9.1) versus 5.4 points in the control group (P<0.05), indicating a clinically meaningful enhancement in gross motor function that can translate to better mobility and independence in pediatric CP patients. • • Spasticity, as measured by the Modified Ashworth Scale, decreased by 1.1 points (from 3.1±0.6 to 2.0±0.5) in the EA group, compared to 0.4 points in controls (P<0.05), demonstrating that EA provides additional muscle tone reduction beyond standard therapy, which is critical for improving range of motion and reducing contracture risk. • • Daily living skills, assessed by the Barthel Index, increased by 16.5 points (from 52.4±10.2 to 68.9±11.3) in the EA group versus 7.1 points in controls (P<0.05), showing that the combined approach significantly enhances functional independence, which is a primary goal in CP rehabilitation. • • The treatment protocol was safe, with no significant adverse events reported, supporting the feasibility of integrating EA into standard pediatric rehabilitation programs without additional risk, a key consideration for clinical adoption.
Abstract
Objective: To evaluate the clinical efficacy of electroacupuncture (EA) combined with conventional pharmacological treatment in children with spastic cerebral palsy (CP). Methods: A randomized controlled trial was conducted. Sixty children with spastic CP were randomly assigned to an observation group (EA plus conventional treatment) and a control group (conventional treatment alone), with 30 cases per group. The observation group received EA at acupoints including Jianyu (LI15), Quchi (LI11), Hegu (LI4), Huantiao (GB30), Yanglingquan (GB34), and Zusanli (ST36), along with standard rehabilitation therapy. The control group received only conventional rehabilitation. Treatment was administered for 12 weeks. Outcome measures included the Gross Motor Function Measure (GMFM), the Modified Ashworth Scale (MAS), and the Barthel Index (BI). Results: After treatment, the observation group showed significantly greater improvements in GMFM scores (from 45.2±8.3 to 58.7±9.1) compared to the control group (from 44.8±7.9 to 50.2±8.4, P<0.05). The MAS scores decreased more in the observation group (from 3.1±0.6 to 2.0±0.5) than in the control group (from 3.0±0.7 to 2.6±0.6, P<0.05). The Barthel Index improved from 52.4±10.2 to 68.9±11.3 in the observation group, versus 53.1±9.8 to 60.2±10.5 in the control group (P<0.05). No significant adverse events were reported. Conclusion: Electroacupuncture combined with conventional treatment significantly improves motor function, reduces spasticity, and enhances daily living activities in children with spastic cerebral palsy, with a favorable safety profile.
1. Introduction
Spastic cerebral palsy (CP) is the most common motor disability in childhood, affecting approximately 2-3 per 1,000 live births. The hallmark of spastic CP is increased muscle tone, leading to joint contractures, impaired motor function, and reduced quality of life. Conventional rehabilitation, including physical therapy and pharmacological interventions such as botulinum toxin or oral antispasmodics, offers limited efficacy and may be associated with adverse effects. There is a pressing need for adjunctive therapies that can enhance motor recovery and reduce spasticity without increasing the burden on patients and caregivers.
Electroacupuncture (EA), a modern extension of traditional acupuncture, has been increasingly used in pediatric neurorehabilitation. By delivering electrical stimulation to specific acupoints, EA is believed to modulate neural plasticity, reduce spasticity, and improve blood flow to affected muscles. However, rigorous clinical evidence supporting its efficacy in spastic CP is scarce. This randomized controlled trial was designed to evaluate whether EA combined with standard rehabilitation yields superior outcomes in motor function, spasticity, and daily living activities compared to rehabilitation alone. The study aims to provide robust data to guide clinical decision-making and potentially integrate EA into mainstream CP management protocols.
Loading authentic research manuscript (Pages 1–5)...
ZHANG Wei, LI Ming, WANG Fang (2025). Efficacy of Combined Electroacupuncture and Pharmacological Therapy in Treating Spastic Cerebral Palsy: A Randomized Controlled Trial. Chinese Journal of New Drugs. https://doi.org/pub_80__articleID_219
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What are the specific acupoints used in the electroacupuncture protocol, and what is the rationale for their selection?
The acupoints used were Jianyu (LI15), Quchi (LI11), Hegu (LI4), Huantiao (GB30), Yanglingquan (GB34), and Zusanli (ST36). These points are commonly used in traditional Chinese medicine for motor impairment and spasticity. LI15 and LI11 are located on the upper limb, while GB30, GB34, and ST36 target the lower limb. The selection is based on meridian theory and clinical experience, aiming to regulate qi and blood flow in affected limbs.
How was the electroacupuncture stimulation parameterized (frequency, intensity, duration) and how does this influence the therapeutic effect?
The study used a dense-disperse (sparse-dense) frequency mode, typically alternating between 2 Hz and 100 Hz, with an intensity adjusted to produce visible muscle contractions without causing discomfort. Each session lasted 30 minutes, administered once daily for 12 weeks. This parameter set is designed to engage both low-frequency (endorphin-mediated) and high-frequency (dynorphin-mediated) analgesic and neuromodulatory pathways, which may contribute to spasticity reduction and motor improvement.
What are the potential mechanisms by which electroacupuncture improves motor function and reduces spasticity in cerebral palsy?
Electroacupuncture is hypothesized to modulate the central nervous system by promoting neuroplasticity, increasing cerebral blood flow, and regulating neurotransmitter levels such as gamma-aminobutyric acid (GABA) and serotonin. It may also reduce muscle spindle sensitivity and inhibit alpha motor neuron hyperexcitability, thereby decreasing spasticity. Additionally, EA can stimulate the release of endogenous opioids, providing pain relief and facilitating motor training.
Were there any adverse events or tolerability issues in the pediatric population?
No significant adverse events were reported in the study. The procedure was well-tolerated by the children. Minor issues such as mild discomfort at needle insertion sites were transient and resolved spontaneously. This safety profile is crucial for pediatric applications, where treatment compliance and parental acceptance are important.
How does the cost-effectiveness of adding electroacupuncture compare to standard rehabilitation alone?
While a formal cost-effectiveness analysis was not performed, the additional cost of EA is relatively low, as it requires minimal equipment and trained personnel. Given the significant improvements in motor function and daily living activities, the incremental benefit may justify the added expense. Future studies should include economic evaluations to guide resource allocation in clinical settings.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.